Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anaerobic bacteria and certain parasites" collectively describes a wide variety of pathogenic **anaerobic microorganisms** (e.g., *Bacteroides*, *Clostridium*, *Fusobacterium*, *Entamoeba histolytica*, *Giardia lamblia*, *Trichomonas vaginalis*) responsible for human and animal infections[1][4][7][3]. These organisms thrive in environments with little or no oxygen and often cause disease when they breach mucosal barriers or invade sterile body sites. Therapeutic drugs used against these organisms commonly exploit their unique anaerobic metabolism, but this designation is not a molecular entity[1][8][5][3].
Drugs often act by interfering with DNA synthesis or energy metabolism unique to anaerobic conditions (e.g., reduction of nitroimidazoles under low-redox environment leading to DNA damage)[1][8][5]
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anaerobic bacteria and certain parasites.